INNSBRUCK, Austria, Nov. 30 /PRNewswire/ -- BIOCRATES Life Sciences GmbH and Pfizer Inc. successfully completed a preclinical pilot study to reveal candidate biomarkers for early events in vascular injury. Results will be presented at the conference Metabolic Markers for Drug Development and Clinical Studies Dec 4-5, 2006 in Florida (http://www.healthtech.com/2006/mbp/index.ASP). "Our targeted and quantitative approach to metabolomics allows one to immediately deduce biologically relevant information from the analytical data", says Klaus Weinberger Ph.D., CSO of BIOCRATES. "Important enzymatic reactions and selected metabolic pathways can be monitored on a fully standardized basis." Pfizer and BIOCRATES are currently discussing future collaborations for novel biomarker development in preclinical and clinical programs. This will allow BIOCRATES to validate and expand their innovative metabolomics approach with the world's largest pharmaceutical company.
Pfizer Inc: Working for a healthier world(TM)
Pfizer Inc, founded in 1849, is dedicated to better health and greater access to healthcare for people and their valued animals. Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment; consistent high- quality manufacturing of medicines, consumer products; and global leadership in corporate responsibility. Every day we help 38 million patients, employ more than 100,000 colleagues, utilize the skills of more than 12,000 medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses - adding both years to life, and life to years. For more information, please visit www.pfizer.com.
BIOCRATES Life Sciences GmbH: Creating knowledge for health
BIOCRATES, the leader in targeted metabolomics, pioneered an integrated mass spectrometry-based technology platform for rapidly extracting detailed information residing in metabolic networks. We use a quantitative approach incorporating numerous internal standards enabling us to immediately identify metabolites, measure their absolute concentrations, and map them to their respective pathways. In addition, BIOCRATES is the only company offering a convenient, disposable kit covering several metabolite classes simultaneously. Our services, kits, and software set the standard for metabolomics in pharmaceutical research. BIOCRATES partners with the most innovative pharmaceutical, biotechnology, and nutritional companies to identify and validate new biomarkers, streamlining the drug development process and revolutionizing clinical diagnostics. For more information, please visit www.biocrates.com.
This release was issued through WebWire(R). For more information visit http://www.webwire.com.
Press Release Contact Information:
Klaus M. Weinberger
Chief Scientific Officer
BIOCRATES Life Sciences
BIOCRATES Life Sciences